D
Dixie-Lee Esseltine
Researcher at Takeda Pharmaceutical Company
Publications - 81
Citations - 6414
Dixie-Lee Esseltine is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Bortezomib & Multiple myeloma. The author has an hindex of 34, co-authored 81 publications receiving 6098 citations. Previous affiliations of Dixie-Lee Esseltine include Johnson & Johnson Pharmaceutical Research and Development & Millennium Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau,Halyna Pylypenko,Sebastian Grosicki,Ievgenii Karamanesht,Xavier Leleu,Maria Grishunina,Grigoriy B Rekhtman,Zvenyslava Masliak,Tadeusz Robak,Anna V Shubina,Bertrand Arnulf,Martin Kropff,James Cavet,Dixie-Lee Esseltine,Huaibao Feng,Suzette Girgis,Helgi van de Velde,William Deraedt,Jean-Luc Harousseau +18 more
TL;DR: The primary objective was to show non-inferiority of subcutaneous versus intravenous bortezomib in terms of overall response rate (ORR) after four cycles in patients with a diagnosis of measurable, secretory multiple myeloma who received one or more dose of drug.
Journal ArticleDOI
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Paul G. Richardson,Edie Weller,Sagar Lonial,Andrzej Jakubowiak,Sundar Jagannath,Noopur Raje,David Avigan,Wanling Xie,Irene M. Ghobrial,Robert L. Schlossman,Amitabha Mazumder,Nikhil C. Munshi,David H. Vesole,Robin Joyce,Jonathan L. Kaufman,Deborah Doss,Diane Warren,Laura E. Lunde,Sarah Kaster,Carol Delaney,Teru Hideshima,Constantine S. Mitsiades,Robert Knight,Dixie-Lee Esseltine,Kenneth C. Anderson +24 more
TL;DR: Lenalidomide-bortezomib-dexamethasone demonstrates favorable tolerability and is highly effective in the treatment of newly diagnosed myeloma.
Journal ArticleDOI
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,David Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,Melissa Alsina,Vincent Rajkumar,Martha Q. Lacy,Andrzej Jakubowiak,William S. Dalton,Anthony Boral,Dixie-Lee Esseltine,David P. Schenkein,Kenneth C. Anderson +23 more
TL;DR: The activity of bortezomib is confirmed and support extended treatment in relapsed multiple myeloma patients tolerating therapy and among responding patients, 56% improved response with longer therapy beyond initial response, leading to continued improvement in overall quality of response.
Journal ArticleDOI
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Maria-Victoria Mateos,Maria-Victoria Mateos,J Hernández,J Hernández,Miguel-T Hernandez,Miguel-T Hernandez,Norma-C. Gutiérrez,Norma-C. Gutiérrez,Luis Palomera,Luis Palomera,M. Fuertes,M. Fuertes,Joaquín Díaz-Mediavilla,Joaquín Díaz-Mediavilla,J.J. Lahuerta,J.J. Lahuerta,Javier de la Rubia,Javier de la Rubia,María-José Terol,María-José Terol,Ana Sureda,Ana Sureda,Joan Bargay,Joan Bargay,Paz Ribas,Paz Ribas,Felipe de Arriba,Felipe de Arriba,Adrian Alegre,Adrian Alegre,Albert Oriol,Albert Oriol,Dolores Carrera,Dolores Carrera,José García-Laraña,José García-Laraña,Ramón García-Sanz,Ramón García-Sanz,Joan Bladé,Joan Bladé,Felipe Prosper,Felipe Prosper,G. Mateo,G. Mateo,Dixie-Lee Esseltine,Dixie-Lee Esseltine,Helgi van de Velde,Helgi van de Velde,Jesús-F San Miguel,Jesús-F San Miguel +49 more
TL;DR: In elderly patients ineligible for transplantation, the combination of bortezomib plus MP appears significantly superior to MP, producing very high CR rates, including immunophenotypic CRs, even in patients with poor prognostic features.
Journal ArticleDOI
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan,Constantine S. Mitsiades,Barb Bryant,Fenghuang Zhan,Wee Chng,Steven Roels,Erik Koenig,Andrew Fergus,Yongsheng Huang,Paul G. Richardson,William L. Trepicchio,Annemiek Broyl,Pieter Sonneveld,John D. Shaughnessy,Leif Bergsagel,David P. Schenkein,Dixie-Lee Esseltine,Anthony Boral,Kenneth C. Anderson +18 more
TL;DR: Responsibility and survival classifiers were developed and shown to be significantly associated with outcome via testing on independent data, and the survival classifier improved on the risk stratification provided by the International Staging System.